{"id":"l50-h12-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL4799196","moleculeType":"Unknown","molecularWeight":"511.94"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor antagonist (ARB) that blocks the AT1 receptor, preventing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting sodium and water excretion. The combination provides synergistic antihypertensive effects through complementary mechanisms.","oneSentence":"L50/H12.5 is a fixed-dose combination of losartan and hydrochlorothiazide that reduces blood pressure by blocking angiotensin II receptors and inhibiting sodium reabsorption in the kidney.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:07.544Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT01299376","phase":"PHASE3","title":"MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-24","conditions":"Hypertension","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-0954H"],"phase":"phase_3","status":"active","brandName":"L50/H12.5","genericName":"L50/H12.5","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L50/H12.5 is a fixed-dose combination of losartan and hydrochlorothiazide that reduces blood pressure by blocking angiotensin II receptors and inhibiting sodium reabsorption in the kidney. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}